Most Read Articles
01 Oct 2015
BLACKMORES ESSENTIAL LIVO – Phosphatidylcholine, Zinc and Chromium Capsules
13 Dec 2016
Any abnormal decrease in a person’s usual bowel movement frequency and/or pain during stool passage is termed as Constipation.
Roshini Claire Anthony, 5 days ago

The incidence of cardiovascular events in the first year following a primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) is comparable between patients given prasugrel and ticagrelor post-surgery, according to results of the PRAGUE-18* trial presented at AHA 2017.

Roshini Claire Anthony, 08 Nov 2017

The presence of vitreous haze, snow banking, and choroidal involvement is associated with an increased risk of antitubercular treatment failure in patients with tubercular (TB) uveitis, according to research by the COTS-1* Study Group.

Fulvestrant, letrozole best first-line endocrine therapy for advanced breast cancer

22 Sep 2017

Fulvestrant and letrozole seem to be the optimal first-line endocrine therapy choices for hormone receptor-positive (HR+) and human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC), according to a network meta-analysis.

The meta-analysis included 27 articles of eight randomized controlled trials (RCTs) corresponding to 3,492 ABC patients. Six monotherapies were investigated: anastrozole, fulvestrant, tamoxifen, exemestane and lestrozole; doses of 250 and 500 mg were considered.

Letrozole yielded better objective response rate (ORR) than tamoxifen (odds ratio [OR], 0.59; 95 percent CI, 0.43 to 0.80) and fulvestrant (OR, 0.54; 0.34 to 0.85) at 250 mg. Exemestane also produced better ORR than fulvestrant (OR, 0.61; 0.37 to 0.97) and tamoxifen (OR, 0.67; 0.48 to 0.91) at 250 mg.

In terms of survival, only one study reported on progression-free survival (PFS) while most looked at time to progression (TTP).  In terms of TTP/PFS, tamoxifen was less effective than both anastrozole (hazard ratio [HR], 0.84; 0.72 to 0.99) and letrozole (HR, 0.70; 0.60 to 0.81).

In comparison, anastrozole (HR, 0.72; 0.56 to 0.93), exemestane (HR, 0.75; 0.57 to 0.97) and letrozole (HR, 0.60; 0.46 to 0.76) all had better TTP/PFS than fulvestrant.

Fulvestrant at 500 mg yielded better TTP/PFS than 250 mg of anastrozole (HR, 1.54; 1.09 to 2.11), exemestane (HR, 1.61; 1.08 to 2.25), tamoxifen (HR, 1.84; 1.24 to 2.55) and fulvestrant (HR, 2.17; 1.34 to 3.11). Only letrozole was not inferior to 500 mg fulvestrant.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2015
BLACKMORES ESSENTIAL LIVO – Phosphatidylcholine, Zinc and Chromium Capsules
13 Dec 2016
Any abnormal decrease in a person’s usual bowel movement frequency and/or pain during stool passage is termed as Constipation.
Roshini Claire Anthony, 5 days ago

The incidence of cardiovascular events in the first year following a primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) is comparable between patients given prasugrel and ticagrelor post-surgery, according to results of the PRAGUE-18* trial presented at AHA 2017.

Roshini Claire Anthony, 08 Nov 2017

The presence of vitreous haze, snow banking, and choroidal involvement is associated with an increased risk of antitubercular treatment failure in patients with tubercular (TB) uveitis, according to research by the COTS-1* Study Group.